文献速递炎症性肠病

色氨酸代谢增强与炎症性肠病活动度相关

Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases.
PubMed 文献 · Gastroenterology · 2017-08-19

研究纳入535例炎症性肠病(IBD)患者和291名对照,发现IBD患者血清色氨酸水平显著低于对照,且与疾病活动度和C反应蛋白呈负相关;色氨酸代谢物喹啉酸升高提示活跃IBD患者色氨酸降解增强。

要点

  • IBD患者血清色氨酸水平显著低于对照,克罗恩病降低幅度大于溃疡性结肠炎。
  • 血清色氨酸与疾病活动度及C反应蛋白呈负相关。
  • 活跃IBD患者色氨酸代谢物喹啉酸升高,提示犬尿氨酸通路激活。

核心结论

  • 在超过500例IBD患者的血清分析中,观察到血清色氨酸水平与疾病活动度呈负相关。
  • 色氨酸代谢物(尤其是喹啉酸)升高提示活跃IBD患者色氨酸降解活性高。
  • 色氨酸缺乏可能促进IBD发生或加重疾病活动。
  • 需要干预性临床研究来确定改变肠道色氨酸通路是否影响IBD严重程度。

研究设计与样本

  • 研究纳入2013年8月至2014年4月在德国连续入组的535例IBD患者(211例溃疡性结肠炎,234例克罗恩病;236例男性),随访至2016年7月。
  • 收集患者及291名匹配的无IBD对照的血清样本,采用高效液相色谱法测定色氨酸水平。
  • 对148例患者和100名对照的血清采用质谱法测定色氨酸代谢物。
  • 对28例患者采用酶联免疫吸附试验测定血清白细胞介素22水平。
  • 对部分活动期UC(n=10)或CD(n=8)患者采集配对粪便和血清样本,通过16S核糖体DNA扩增子测序分析粪便微生物群组成与血清色氨酸水平的关联。

主要发现

  • IBD患者血清色氨酸水平显著低于对照(P=5.3×10-6),克罗恩病患者降低幅度(vs 对照;P=1.1×10-10)大于溃疡性结肠炎患者(vs 对照;P=2.8×10-3)。
  • 血清色氨酸水平与疾病活动度或C反应蛋白水平呈负相关。
  • 与对照相比,IBD患者结肠活检中编码色氨酸2,3-双加氧酶-2和溶质载体家族6成员19(又称B0AT1)的信使RNA水平显著降低,而编码吲哚胺2,3-双加氧酶-1的信使RNA水平显著升高。
  • 粪便微生物群组成与血清色氨酸水平相关。
  • 与对照相比,IBD患者色氨酸代谢物分析显示犬尿氨酸通路激活,基于喹啉酸水平高。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要干预性临床研究来确定改变肠道色氨酸通路是否影响IBD严重程度。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Administration of tryptophan and some of its metabolites reduces the severity of colitis in mice, whereas removing tryptophan from the diet increases susceptibility to colitis. Transfer of the intestinal microbiome transfers the colitogenic phenotype from tryptophan starved animals to normally nourished mice. We aimed to systematically evaluate serum levels of tryptophan and its metabolites in patients with inflammatory bowel diseases (IBD), and study their association with clinical and serologic features. METHODS: We studied 535 consecutive patients with IBD (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD]; 236 male), enrolled in Germany from August 2013 through April 2014 and followed until July 2016. Serum samples were collected from patients and 291 matched individuals without IBD (controls); levels of tryptophan were measured using high-performance liquid chromatography. Metabolites of tryptophan were measured in serum from 148 patients and 100 controls by mass spectrometry. We measured levels of interleukin 22 in serum from 28 patients by enzyme-linked immunosorbent assay. Paired stool and serum samples were collected from a subset of patients with active UC (n = 10) or CD (n = 8) to investigate associations between serum levels of tryptophan and composition of the fecal microbiota, analyzed by 16S ribosomal DNA amplicon sequencing. We used real-time polymerase chain reaction to measure levels of messenger RNAs in colonic biopsies from 60 patients with UC, 50 with CD, and 30 controls. We collected information on patients' disease activity scores, medications, laboratory assessments, and clinical examinations during recruitment and follow-up visits. RESULTS: Serum levels of tryptophan were significantly lower in patients with IBD than in controls (P = 5.3 × 10-6) with a stronger reduction in patients with CD (vs control; P = 1.1 × 10-10) than UC (vs control; P = 2.8 × 10-3). We found a negative correlation between serum levels of tryptophan and disease activity or levels of C-reactive protein. Levels of messenger RNAs encoding tryptophan 2,3-dioxygenase-2 and solute carrier family 6 member 19 (also called B0AT1) were significantly decreased in colonic biopsies from patients with IBD compared with controls, whereas level of messenger RNA encoding indoleamine 2,3-dioxygenase-1 was significantly increased. The composition of the fecal microbiota associated with serum levels of tryptophan. Analysis of tryptophan metabolites revealed activation of the kynurenine pathway, based on high levels of quinolinic acid, in patients with IBD compared with controls. Serum concentration of interleukin 22 associated with disease activity in patients with IBD; there was an inverse association between levels of interleukin 22 and serum levels of tryptophan. CONCLUSIONS: In an analysis of serum samples from more than 500 patients with IBD, we observed a negative correlation between serum levels of tryptophan and disease activity. Increased levels of tryptophan metabolites-especially of quinolinic acid-indicated a high activity of tryptophan degradation in patients with active IBD. Tryptophan deficiency could contribute to development of IBD or aggravate disease activity. Interventional clinical studies are needed to determine whether modification of intestinal tryptophan pathways affects the severity of IBD.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Nikolaus S, Schulte B, Al-Massad N, et al. Increased Tryptophan Metabolism Is Associated With Activity of Inflammatory Bowel Diseases. Gastroenterology. 2017. PMID: 28827067. doi:10.1053/j.gastro.2017.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。